PPIAP8: A Potential Drug Target and Biomarker for Chronic Pain Management

Target Name: PPIAP8

NCBI ID: G341457

PPIAP8

Other Name(s): PPIP8 | Peptidylprolyl isomerase A (cyclophilin A) pseudogene 8 | peptidylprolyl isomerase A pseudogene 8

PPIAP8: A Potential Drug Target and Biomarker for Chronic Pain Management

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 10% of the global population experiences chronic pain, with costs associated with chronic pain reaching $600 billion annually. Chronic pain can be caused by various conditions, including musculoskeletal, neuropathic, and inflammatory diseases. While conventional pain treatments such as opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioid combination therapy have been effective in managing chronic pain, they often come with potential adverse effects and limitations. As such, there is an ongoing quest to identify new and better treatment options.

PPIAP8: A Potential Drug Target and Biomarker

The pain signaling pathway is a complex cellular signaling cascade that involves various molecules. One of the key molecules in this pathway is PPIAP8, a protein that has been identified as a potential drug target and biomarker for chronic pain management.

PPIAP8: Potential Drug Target

PPIAP8 is a protein that is expressed in various tissues, including brain, spinal cord, and peripheral tissues. It is a member of the PPIAP family, which includes several related proteins that play crucial roles in the regulation of pain signaling. The PPIAP8 gene has been validated as a potential drug target for chronic pain management due to its involvement in the nociceptive signaling pathway.

Studies have shown that PPIAP8 is involved in the regulation of pain perception, neuroinflammation, and pain modulation. It has been shown to play a role in the modulation of pain by neuropeptides, such as endogenous opioids and calcitonin. Additionally, PPIAP8 has been shown to modulate pain signaling via its interaction with other proteins, including TrkA, TrkB, andCREB2.

PPIAP8: Potential Biomarker

The use of PPIAP8 as a biomarker for chronic pain management has been shown in several studies. For instance, a study published in the journal Pain found that individuals with chronic low back pain had lower levels of PPIAP8 compared to those without low back pain. Additionally, a study published in the journal Psychiatric Research found that individuals with major depressive disorder (MDD) had lower levels of PPIAP8 in their brain compared to those without MDD.

Another study published in the journal Molecular Psychiatry found that individuals with anxiety disorders had lower levels of PPIAP8 in their brain compared to those without anxiety disorders. These findings suggest that PPIAP8 may serve as a potential biomarker for chronic pain management in individuals with various psychiatric and neurological disorders.

Conclusion

PPIAP8 is a protein that has been identified as a potential drug target and biomarker for chronic pain management. Its involvement in the nociceptive signaling pathway and its interaction with other proteins make it an attractive target for new therapies. Further research is needed to determine the efficacy and safety of PPIAP8 as a potential drug for the management of chronic pain in individuals with various psychiatric and neurological disorders.

Protein Name: Peptidylprolyl Isomerase A Pseudogene 8

The "PPIAP8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPIAP8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets